ReviewHuman vaccines & immunotherapeutics2014
Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design.
Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 24 citations in OpenAlex.
- Regulatory T cell epitope content in human antibodies decreases during maturation.Frontiers in immunology · 2025Article
- Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice.Human vaccines & immunotherapeutics · 2022Article
- Maternally-Derived Antibodies Protect against Challenge with Highly Pathogenic Avian Influenza Virus of the H7N3 Subtype.Vaccines · 2019Article
- Memory CD4European journal of immunology · 2019Article
- Discovery of T-cell Driven Subunit Vaccines from Zika Virus Genome: An Immunoinformatics Approach.Interdisciplinary sciences, computational life sciences · 2017Article
- A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza.Journal of virology · 2017Article
- A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines.Scientific reports · 2017Article
- Avian and Human Seasonal Influenza Hemagglutinin Proteins Elicit CD4 T Cell Responses That Are Comparable in Epitope Abundance and Diversity.Clinical and vaccine immunology : CVI · 2017Article
- Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- Article
- Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes.Clinical and vaccine immunology : CVI · 2015Article
- Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.Antimicrobial agents and chemotherapy · 2015Article
- Newcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses.Journal of virology · 2015Article
- Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases.Expert review of vaccines · 2015Review
- Article
- Development of cross-protective influenza a vaccines based on cellular responses.Frontiers in immunology · 2015Review
- H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance.Human vaccines & immunotherapeutics · 2015Article
- iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines.Human vaccines & immunotherapeutics · 2015Article
- Immune camouflage: relevance to vaccines and human immunology.Human vaccines & immunotherapeutics · 2014Article
- Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection.Frontiers in microbiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel avian-origin H7N9 influenza strain emerged in China in April 2013. Since its re-emergence in October-November 2013, the number of reported cases has accelerated; more than 220 laboratory-confirmed cases and 112 deaths (case fatality rate of 20-30%) have been reported. The resurgence of H7N9 has re-emphasized the importance of making faster and more effective influenza vaccines than those that are currently available. Recombinant H7 hemagglutinin (H7-HA) vaccines have been produced, addressing the first problem. Unfortunately, these recombinant subunit vaccine products appear to have failed to address the second problem, influenza vaccine efficacy. Reported unadjuvanted H7N9 vaccine seroconversion rates were between 6% and 16%, nearly 10-fold lower than rates for unadjuvanted vaccine seroconversion to standard H1N1 monovalent (recombinant) vaccine (89% to pandemic H1N1). Could this state of affairs have been predicted? As it turns out, yes, and it was. In that previous analysis of available H7-HA sequences, we found fewer T-cell epitopes per protein than expected, and predicted that H7-HA-based vaccines would be much less antigenic than recent seasonal vaccines. Novel approaches to developing a more immunogenic HA were offered for consideration at the time, and now, as the low immunogenicity of H7N9 vaccines appears to indicate, they appear to be even more relevant. More effective H7N9 influenza vaccines can be produced, provided that the role of T-cell epitopes is carefully considered, and accumulated knowledge about the importance of cross-conserved epitopes between viral subtypes is applied to the design of those vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.